Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.
Shi X et al.
Journal of Advanced Research, 2025
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study.
Jiang H et al.
Translational Lung Cancer Research, 2024
LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
Lagoudaki ED et al.
Cancers, 2024
Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.
Caballé-Perez E et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.
Grabski IN et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2024
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ et al.
Pathology Oncology Research : Por, 2024
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.
De Saint Basile H et al.
Exploration of Targeted Anti-tumor Therapy, 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T et al.
Cancer Medicine, 2023
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH et al.
Cancer Research and Treatment, 2023
Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.
Yousef A et al.
Research Square, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK et al.
Current Oncology (toronto, Ont.), 2023
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Bironzo P et al.
Cancer, 2023
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
Li S et al.
Cancers, 2023
Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.
Moorthi S et al.
Biorxiv : the Preprint Server for Biology, 2023
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.
Veccia A et al.
Targeted Oncology, 2023
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer.
Malhotra J et al.
Journal of Thoracic Disease, 2022
STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.
Pons-Tostivint E et al.
Cells, 2021
Malfeasance of KRAS mutations in carcinogenesis.
Tripathi R et al.
Clinical and Experimental Medicine, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U et al.
European Journal of Cancer (oxford, England : 1990), 2021
Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Xu S et al.
Bmc Cancer, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A et al.
Translational Lung Cancer Research, 2021
Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma.
de Malet A et al.
Therapeutic Advances in Medical Oncology, 2021
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.
Papillon-Cavanagh S et al.
Esmo Open, 2020
A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L et al.
Translational Oncology, 2020
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo JV et al.
Lung Cancer (amsterdam, Netherlands), 2019
Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients.
Boldrini L et al.
Biomedical Reports, 2018
Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2018
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N et al.
Oncotarget, 2017
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Anai S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Prognostic and Predictive Value of KRAS Mutation in NSCLC.
Yamamoto S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS et al.
International Journal of Cancer, 2014
Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
Kunze K et al.
Pathology, Research and Practice, 2014
Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.
Sherwood JL et al.
Plos One, 2014
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL et al.
British Journal of Cancer, 2009
Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review.
Andrews LJ et al.
Neuro-oncology Advances, 0